New Data At ESC Congress 2021 Shows Repatha® (evolocuma

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data from the HUYGENS Phase 3 study showing that Repatha® (evolocumab) in addition to optimized...

Related Keywords

China , Puerto Rico , Australia , Monash , South Australia , Japan , Melbourne , Victoria , Coll Cardiol , Michael Strapazon , Trish Rowland , Stephenj Nicholls , Davidm Reese , Exchange Commission , Amgen , European Union , Drug Administration , Monash University Victorian Heart Institute , World Health Organization , Beigene Ltd , Cardiovascular Therapeutic , Primary Hyperlipidemia , Cardiovascular Outcomes Trial , Pharmaceutical Precautions , Adaptive Biotechnologies , Thousand Oaks , Amgen Data , Coronary Artery Disease , Analysis From , World Health , Accessed July , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Biotechnology , Roadcast Feed Annoucement , Clinical Trials Amp Medical Discoveries , Trade Show News ,